Characteristics of patients with AIRD and immunocompetent controls
| Variable | AIRD all (n=308) | IC (n=296) |
| Demographics | ||
| Age, median (IQR) | 59.0 (46.3–66.0) | 40.0 (31.0–60.0) |
| Age ≥60 years, n (%) | 147 (47.7) | 76 (25.7) |
| Female sex, n (%) | 209 (67.9) | 199 (67.2) |
| BMI, median (IQR)* | 25.0 (22.2–28.78) | – |
| Comorbidities | ||
| Cardiovascular disease, n (%) | 118 (38.3) | 69 (23.3) |
| Type 2 diabetes, n (%) | 23 (7.5) | 13 (4.4) |
| Respiratory disease, n (%) | 41 (13.3) | 32 (10.8) |
| Vaccination | ||
| BNT162b2, n (%) | 233 (75.6) | 173 (58.4) |
| mRNA-1273, n (%) | 27 (8.8) | 0 |
| AZD1222, n (%) | 22 (7.1) | 32 (10.8) |
| AZD1222+mRNA, n (%) | 26 (8.4) | 91 (30.7) |
| AZD1222+BNT162b2 | 20 | 91 |
| AZD1222+mRNA-1273 | 6 | 0 |
| Vaccine interval in days, median (IQR) | 41.0 (28.3–42.0) | 21.0 (21.0–71.0) |
| Second vaccination to testing in days, median (IQR) | 18.0 (14.0–33.8) | 26.0 (21.0–28.0) |
| Vaccination response | ||
| Neutralising capacity (%), median (IQR) | 90.8 (54.2–95.9) | 96.5 (93.5–97.1) |
| Anti-RBD-IgG (S/CO), median (IQR) | 5.6 (2.0–6.6) | 6.7 (6.3–7.1) |
| Positive neutralising capacity, n (%)† | 258 (83.8) | 292 (98.6) |
| Positive anti-RBD-IgG level, n (%)‡ | 246 (79.9) | 293 (99.0) |
*Data were only available for patients with AIRD.
†Defined as neutralising capacity against SARS-CoV-2 ≥30%.
‡Defined as anti-RBD-IgG levels >1.0 S/CO.
AIRD, autoimmune rheumatic diseases; BMI, body mass index; IC, immunocompetent controls; S/CO, signal/cut-off.